Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 39 - Medicinal preparations containing antigens or antibodies
Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248)
03/2005
03/22/2005US6869793 Recombinant MVA virus expressing dengue virus antigens, and the use thereof in vaccines
03/22/2005US6869787 Which lack N-glycosidase-rRNA activity; kits
03/22/2005US6869608 Peptides derived from a retrovirus of the HIV group and their use
03/22/2005US6869607 Vaccine formulations
03/22/2005US6869605 Anticarcinogenic agents
03/22/2005US6869592 Method and antibody for imaging lung cancer
03/22/2005CA2135630C Hiv protein epitopes immunologically homologous to hla
03/22/2005CA2134761C Synthetic peptide vaccines for dental caries
03/22/2005CA2127541C Recombinant swinepox virus
03/22/2005CA2103059C Method for making humanized antibodies
03/17/2005WO2005024061A2 Compounds and methods for modulation of dna replication
03/17/2005WO2005024038A2 Process for producing a capsular polysaccharide for use in conjugate vaccines
03/17/2005WO2005024032A2 Targeting adenoviral vectors to dendritic cells
03/17/2005WO2005024022A1 Tick engorgement factor proteins
03/17/2005WO2005024019A1 Inducible bacterial expression system utilising sspa promoter from salmonella
03/17/2005WO2005024005A1 Novel salmonella bacteriophage and uses thereof
03/17/2005WO2005023992A2 Compositions and methods for inhibiting white spot syndrome virus (wssv) infection
03/17/2005WO2005023871A1 An agent for selective suppression disease-associated auto-reactive b-cells
03/17/2005WO2005023864A1 Peptide-based immunization therapy for treatment of atherosclerosis
03/17/2005WO2005023862A2 Homogeneous preparations of il-28 and il-29
03/17/2005WO2005023853A1 Protease-resistant seb variant and vaccine containing the same
03/17/2005WO2005023851A1 Plasminogen/plasmin binding polypeptides and nucleic acids therefore
03/17/2005WO2005023849A2 Antigenic peptides of rabies virus and uses thereof
03/17/2005WO2005023848A2 Adenoviral epitopes
03/17/2005WO2005023837A2 Ebola peptides and immunogenic compositions containing same
03/17/2005WO2005023830A2 Ozonation products of cholesterol for the treatment and prevention of atherosclerosis and/or cardiovascular diseases
03/17/2005WO2005023328A2 Methods for intradermal delivery of therapeutics agents
03/17/2005WO2005023313A1 Lentivirus vector-based approaches for generating an immune response to hiv humans
03/17/2005WO2005023299A2 Therapeutic human anti-mhc class ii antibodies and their uses
03/17/2005WO2005023297A1 Composition for the prophylaxis/treatment of hbv infections and hbv-mediated diseases
03/17/2005WO2005023296A1 Treatment of rheumatic diseases
03/17/2005WO2005023295A2 Naturally processed immunodominant peptides derived from neisseria meningitidis porin a protein and their use
03/17/2005WO2005023293A1 Vaccine composition comprising il-12 adjuvant encapsulated in controlled-release microsphere
03/17/2005WO2005023205A2 Compositions and methods for yersinia pestis treatment
03/17/2005WO2005023187A2 Inhibitor of cardiac tachyarrhythmias
03/17/2005WO2005023177A2 Human monoclonal antibodies against bacillusanthracis protective antigen
03/17/2005WO2005004911B1 Adjuvant combinations of liposomes and mycobacterial lipids for immunization compositions and vaccines
03/17/2005WO2005002570A8 Use of an aziridino compound to selectively inactivate parasites in biological compositions
03/17/2005WO2004103408A3 Vaccine composition comprising iron phosphate as a pharmaceutical aid to said vaccine
03/17/2005WO2004103313A3 Methods of reducing vascular permeability in tissue by inhibition of tissue plasminogen activator (tpa) and tpa inhibitors useful therein
03/17/2005WO2004087749A3 Nontypeable haemophilus influenzae virulence factors
03/17/2005WO2004076619A3 New dengue and west nile viruses proteins and genes coding the foregoing, and their use in vaccinal, therapeutic and diagnostic applications
03/17/2005WO2004074434A3 Methods and compositions for administering therapeutic and diagnostic agents
03/17/2005WO2004060291A3 Uses of mammalian cytokine; related reagents
03/17/2005WO2004056862A3 Immunogenic compositions to the cck-b/gastrin receptor and methods for the treatment of tumors
03/17/2005WO2004050846A3 Wall teichoic acid as a target for anti-staphylococcal therapies and vaccines
03/17/2005WO2004041851A3 Vaccine
03/17/2005WO2004022729A8 Method for the cultivation of primary cells and for the amplification of viruses under serum free conditions
03/17/2005WO2004019761A3 Methods of treating age-related defects and diseases
03/17/2005WO2004016750A3 FcϜRIIB-SPECIFIC ANTIBODIES AND METHODS OF USE THEREOF
03/17/2005WO2003104429B1 Genes overexpressed by ovarian cancer and their use in developing novel therapeutics
03/17/2005WO2003101484A9 Compositions and methods for transepithelial molecular transport
03/17/2005WO2003011898A3 Synthetic or natural peptides binding protein phosphatase 2a, identification method and uses
03/17/2005WO2002100343A3 N-terminally truncated galectin-3 and antibodies for treating cancer
03/17/2005US20050059802 chimeric peptide of a peptide wherein the carboxyl terminus of the first portion (comprising a naturally-occurring internal peptide cleavage product) is linked to the amino terminus of the second portion (comprising a T helper cell epitope)
03/17/2005US20050059626 Methods of preventing and treating viral infections using immunomodulatory polynucleotide sequences
03/17/2005US20050059625 Immunostimulatory nucleic acid molecules
03/17/2005US20050059624 Application of mRNA for use as a therapeutic against tumour diseases
03/17/2005US20050059592 EphA2 and hyperproliferative cell disorders
03/17/2005US20050059591 Prevention and treatment of amyloidogenic disease
03/17/2005US20050059578 Compositions comprising phosphatidylethanolamine-binding peptides linked to anti-viral agents
03/17/2005US20050059143 Using formaldehyde and phenol mixture to sterilize and/or depyrogenate blood products; viricides; parasiticides; antiprotozoa agents
03/17/2005US20050059121 Colony stimualting factor for use in animal vaccination and as nonspecific immunity stimulant; veterinary medicine
03/17/2005US20050059108 Expression vector comprising nucleotide sequences coding neurotransmitter for use in prevention and treatment of obesity, anorexia, energy imbalance, diabetes, dyslipidemia, hypertension and/or insulin resistance
03/17/2005US20050059099 PSCA: prostate stem cell antigen and uses thereof
03/17/2005US20050059093 Method for detecting modulators of Notch signalling
03/17/2005US20050059087 Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof
03/17/2005US20050059040 Guidance receptor protein for use as tool in identifying modlator for use in treatment and preventio of nervous system disorders
03/17/2005US20050059018 Virulence-associated nucleic acids and proteins and uses thereof
03/17/2005US20050059008 Compositions and methods for identifying and targeting cancer cells of alimentary canal origin
03/17/2005US20050058999 Gene involved in apoptosis regulation
03/17/2005US20050058993 Method and device for detecting feline immunodeficiency virus
03/17/2005US20050058992 Method and device for detecting feline immunodeficiency virus
03/17/2005US20050058988 for identification and vaccination of human papillomavirus;
03/17/2005US20050058983 Immunoglobulin which specifically binds to lymphadenopathy associated viral glycoprotein 120 for use as tool in prevention and treatment of viral infection; immunotherapy
03/17/2005US20050058668 Allogeneic immunotherapy agent for cancer therapy; vaccine
03/17/2005US20050058667 Adjuvants for use in vaccines
03/17/2005US20050058664 Infectious bursal disease virus (IBDV) mutant expressing virus neutralising epitopes specific for classic-and variant IBDV strains
03/17/2005US20050058663 Vaccines against Mycobacterium for mouth administering
03/17/2005US20050058662 Novel type III secretion pathway in Aeromonas salmonicida, and uses therefor
03/17/2005US20050058661 Methods and compositions for vaccination comprising nucleic acid and/or polypeptide sequences of the genus Borrelia
03/17/2005US20050058660 Novel surface antigen
03/17/2005US20050058658 Treatment for HIV infections by stimulation of immune response in subjects by immunotherapy using proteins with immune therapy response to treat viruses
03/17/2005US20050058657 Vaccines for treatment of Aids
03/17/2005US20050058656 Peptide sequences for immunization in veterinary medicine
03/17/2005US20050058655 Vaccine and kit for viral disease in swine and diagnosis of diseases
03/17/2005US20050058654 For therapy of cancers, autoimmune diseases, immunodeficiency diseases, reperfusion injuries, and neurodegenerative diseases
03/17/2005US20050058653 Prevention of myocarditis, abortion and intrauterine infection associated with porcine circovirus-2
03/17/2005US20050058648 Antibodies against caspase-8, their preparation and use
03/17/2005US20050058647 Newly identified polypeptide and polynucleotides for diagnosis of new compounds
03/17/2005US20050058644 Compounds for treatment of cancer using lymphocytes, monoclonal antibodies and interferons
03/17/2005US20050058642 Antagonists and agonists of LDCAM and methods of use
03/17/2005US20050058641 Tolerance induction and maintenance in hematopoietic stem cell allografts
03/17/2005US20050058639 Antibodies directed to monocyte chemo-attractant protein-1 (MCP-1) and uses thereof
03/17/2005US20050058626 Vaccine against pathogens
03/17/2005US20050058623 Use of gp130 activators in diabetic neuropathy
03/17/2005CA2540198A1 Tick engorgement factor proteins
03/17/2005CA2538691A1 Process for producing polysaccharide for conjugate vaccine
03/17/2005CA2538141A1 Therapeutic human anti-mhc class ii antibodies and their uses
03/17/2005CA2537995A1 Compositions and methods for inhibiting white spot syndrome virus (wssv) infection
1 ... 1076 1077 1078 1079 1080 1081 1082 1083 1084 1085 1086 1087 1088 1089 1090 1091 1092 1093 1094 1095 1096 ... 1823